ADC Payload Summit

Kongressthemen
The ADC payload landscape is shifting rapidly. Driven by clinical successes of lower potency topoisomerase I inhibitors and as payloads that elicit novel modes of action continue to gain momentum, ADC developers are looking to harness these payload technologies to diversify the mechanism of action, widen the therapeutic index and expand the disease indications that ADCs can see a benefit in.

Kongressorganizer (PCO)
Hanson Wade

Anmerkungen
Brochure: https://go.evvnt.com/2225021-3?pid=4832

Speakers: David Thurstonz, Professor - Drug Discovery, King's College London School of Medicine, Francesca Zammarchi, Chief Scientific Officer, Myricx Bio, and more

https://go.evvnt.com/2225021-2?pid=4832

Frau Alice Grant